Kadmon bags a quick win for its graft-versus-host disease drug ahead of August PDUFA date
About a year and a half after Kadmon trumpeted “knock-your-socks-off” results for its chronic graft-versus-host disease (GVHD) treatment, the FDA has followed through with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
